NEW YORK (GenomeWeb News) – Alnylam today said that it has joined GlaxoSmithKline in contributing more than 1,500 issued or pending patents covering RNA interference technology to a patent pool for neglected tropical diseases.

The patent pool was established by London-based GlaxoSmithKline earlier this year to aid in the discovery and development of new medicines for treating 16 neglected tropical diseases, as defined by the US Food and Drug Administration, in the world's least developed countries.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

At his FDA Law Blog, Jeffrey Gibbs discusses FDA's technical assistance for the draft Diagnostic Accuracy and Innovation Act.

The New York Times reports that genetic testing has uncovered unfaithful penguins at a Utah aquarium.

Cancer researcher loses funding under new Wellcome Trust anti-bullying policies, the Guardian reports.

In Science this week: International Wheat Genome Sequencing Consortium publishes the bread wheat cultivar Chinese Spring reference genome, and more.